Alzheimer’s: The Puzzle, The Partners, The Path Forward

  Alzheimer’s: The Puzzle, The Partners, The Path Forward

Join Us for a Discussion about Challenges and Opportunities In Pre-Competitive
          Partnerships, Clinical Trial Enrollment and Public Policy

Business Wire

WASHINGTON -- September 23, 2013

Please join the Pharmaceutical Research and Manufacturers of America (PhRMA),
the Alzheimer’s Association and the Alzheimer’s Drug Discovery Foundation at
an October 23, 2013 forum focused on the primary hurdles to combating
Alzheimer’s Disease (AD), a debilitating neurodegenerative disease that
currently afflicts more than 5 million people in the U.S.

In an effort to catalyze progress in AD innovation and move medical science
closer to our shared goal of bringing new preventative and therapeutic
solutions to Alzheimer’s patients, we are convening top industry and academic
scientists, patients, policymakers, and other stakeholders for a day of open
engagement and dialogue. Key topics of focus will include how to accelerate
the impact of pre-competitive collaborative partnerships, challenges currently
facing clinical trial recruitment specific to Alzheimer’s and new paths
forward for science and policy. During the lunch, we will also feature patient
stories about the devastating impact this disease has on families and
communities across the U.S.

Who:     Suzanne Corker, PhD, Professor of Behavioral Neuroscience, Emerita,
         Massachusetts Institute of Technology;
         Neil Buckholtz, PhD, Director, Division of Neuroscience Office,
         National Institute on Aging;
         Bill Chin, MD, Executive Vice President, Scientific & Regulatory
         Affairs, PhRMA;
         Howard Fillit, MD, Executive Director and Chief Science Officer,
         Alzheimer’s Drug Discovery Foundation;
         Maria Freire, PhD, President, Foundation of NIH;
         Tim Garnett, MD, Chief Medical Officer and Senior Vice President, Eli
         Nicholas Kozaur, MD, Acting Clinical Team Lead at the FDA’s Division
         of Neurology Products;
         Eric Parker, PhD, Executive Director and Neuroscience Site Lead,
         Merck Research Laboratories;
         Heather Snyder, PhD, Director, Medical and Scientific Relations,
         Alzheimer’s Association;
         Stevin Zorn, PhD, Executive Vice President of R&D, Lundbeck;
         And others
What:    Alzheimer’s: The Puzzle, The Partners, The Path Forward
         Sponsored by: PhRMA, the Alzheimer’s Association and the Alzheimer’s
         Drug Discovery Foundation
When:    Wednesday, October 23, 2013, 9:00am – 5:45pm
Where:   National Academy of Sciences Building
         2102 Constitution Ave., NW
         Washington, DC 2003

*** Due to limiting seating capacity, please fill out the registration form
found on by October 16, 2013.

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents
the country’s leading innovative biopharmaceutical research and biotechnology
companies, which are devoted to discovering and developing medicines that
enable patients to live longer, healthier, and more productive lives. Since
2000, PhRMA member companies have invested approximately $550 billion in the
search for new treatments and cures, including an estimated $48.5 billion in
2012 alone.

Find PhRMA Online:

  *Website –
  *Facebook –
  *Blog –
  *Twitter – and
  *YouTube –

For information on how innovative medicines save lives, visit:
For information on the Partnership for Prescription Assistance, visit:
For information on ensuring the flow of medicines during public health
emergencies, visit

Photos/Multimedia Gallery Available:



Jenni Brewer, 202-835-3460
Press spacebar to pause and continue. Press esc to stop.